FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.12  |  FHIR Version n/a  User: [n/a]

785688002: Carbidopa anhydrous (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2019. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module
3767988015 Carbidopa anhydrous en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core
3767989011 Carbidopa anhydrous (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core
4351501000052115 karbidopa, vattenfritt sv Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT Sweden NRC maintained module (core metadata concept)

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Carbidopa anhydrous Has disposition (attribute) Dihydroxyphenylalanine decarboxylase inhibitor (disposition) true Inferred relationship Some
Carbidopa anhydrous Is a Dihydroxyphenylalanine true Inferred relationship Some
Carbidopa anhydrous Is modification of (attribute) Carbidopa true Inferred relationship Some
Carbidopa anhydrous Has disposition (attribute) Dopamine receptor agonist (disposition) true Inferred relationship Some
Carbidopa anhydrous Is a Substance with dihydroxyphenylalanine decarboxylase inhibitor mechanism of action (substance) true Inferred relationship Some
Inbound Relationships Type Active Source Characteristic Refinability Group
Product containing precisely carbidopa anhydrous (as carbidopa) 10 milligram and levodopa 100 milligram/1 each conventional release orodispersible tablet (clinical drug) Has basis of strength substance (attribute) True Carbidopa anhydrous Inferred relationship Some 2
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 250 mg orodispersible tablet Has basis of strength substance (attribute) True Carbidopa anhydrous Inferred relationship Some 2
Carbidopa anhydrous (as carbidopa) 18.75 mg and entacapone 200 mg and levodopa 75 mg oral tablet Has basis of strength substance (attribute) True Carbidopa anhydrous Inferred relationship Some 3
Carbidopa anhydrous (as carbidopa) 31.25 mg and entacapone 200 mg and levodopa 125 mg oral tablet Has basis of strength substance (attribute) True Carbidopa anhydrous Inferred relationship Some 3
Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 100 milligram/1 each conventional release orodispersible tablet (clinical drug) Has basis of strength substance (attribute) True Carbidopa anhydrous Inferred relationship Some 2
Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram/1 each conventional release oral tablet (clinical drug) Has basis of strength substance (attribute) True Carbidopa anhydrous Inferred relationship Some 1
Product containing precisely carbidopa anhydrous (as carbidopa) 25 milligram and levodopa 250 milligram/1 each conventional release oral tablet (clinical drug) Has basis of strength substance (attribute) True Carbidopa anhydrous Inferred relationship Some 2
Product containing precisely carbidopa anhydrous (as carbidopa) 10 milligram and levodopa 100 milligram/1 each conventional release oral tablet (clinical drug) Has basis of strength substance (attribute) True Carbidopa anhydrous Inferred relationship Some 2
Carbidopa anhydrous (as carbidopa) 25 mg and levodopa 100 mg oral tablet Has basis of strength substance (attribute) True Carbidopa anhydrous Inferred relationship Some 2
Carbidopa anhydrous (as carbidopa) 12.5 mg and levodopa 50 mg oral tablet Has basis of strength substance (attribute) True Carbidopa anhydrous Inferred relationship Some 2

This concept is not in any reference sets

Back to Start